AbCellera Biologics Inc. ABCL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -289%+803pp | -1,091.6%-468pp | -623.8%— | —— | |
| Net margin | -194.9%+370pp | -564.8%-180pp | -385%— | —— | |
| EBITDA margin | -259.5%+553pp | -812.9%-253pp | -559.6%— | —— | |
| Free cash flow margin | -231.7%+417pp | -648.4%-331pp | -317.7%— | —— | |
| Returns | |||||
| Return on equity | -14.5%+0.3pp | -14.7%-2.5pp | -12.3%— | —— | |
| Return on assets | -10.8%+0.7pp | -11.4%-1.8pp | -9.7%— | —— | |
| Return on invested capital | -22.3%+8.2pp | -30.5%-7.1pp | -23.4%— | —— | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×-0.3× | 0.3×0.0× | |
| Liquidity | |||||
| Current ratio | 11.3×+1.5× | 9.8×+2.5× | 7.3×-1.3× | 8.7×+1.0× | |
| Quick ratio | 11.2×+1.4× | 9.8×+2.5× | 7.3×-1.3× | 8.7×+1.0× | |
| Cash ratio | 2×0.0× | 2×+0.9× | 1.1×-2.1× | 3.3×-0.7× | |
| Leverage | |||||
| Debt-to-equity | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×+0.1× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $3.24-9.8% | $3.59-10.0% | $3.99+1.7% | $3.92+21.6% | |
| Valuation | |||||
| Market capitalization | $1.02B+18.3% | $865.42M-47.8% | $1.66B-42.8% | $2.9B-28.0% | |
| Enterprise value | $1.04B+34.1% | $774.46M-51.6% | $1.6B-38.3% | $2.59B-27.8% | |
| Price / sales | 13.6×-16.4× | 30×-13.6× | 43.6×+37.6× | 6×-4.8× | |
| Price / book | 1.1×+0.2× | 0.8×-0.6× | 1.4×-0.9× | 2.4×-1.6× | |
| EV / sales | 13.8×-13.0× | 26.9×-15.2× | 42.1×+36.8× | 5.3×-4.2× | |
| Free cash flow yield | -17%+4.6pp | -21.6%-14.3pp | -7.3%— | —— | |
| Earnings yield | -14.3%+4.5pp | -18.8%-10.0pp | -8.8%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AbCellera Biologics Inc.'s ratios come from?
- Every ratio is computed from AbCellera Biologics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.